Reactivos e instrumentos para inmunología, biología celular y biología molecular.
 
> Glycochenodeoxycholic acid sodium salt [16564-43-5]

Glycochenodeoxycholic acid sodium salt [16564-43-5]

Imprimir Imprimir
Por favor conéctese

Referencia HY-N2334A-100mg

embalaje : 100mg

Marca : MedChemExpress


Descripciòn

Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC)[1][2][3][4].

IC50 & Target

Microbial Metabolite

 

Human Endogenous Metabolite

 

Cellular Effect
Cell Line Type Value Description References
CHO EC50
3.88 μM
Compound: 4b, glyco
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
[PMID: 18307294]
HET-1A CC50
729 μM
Compound: 3, TCDCA
Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 20713311]
In Vitro

Glycochenodeoxycholic acid sodium salt (0-100 μM, 6 h) significantly increases the amount of dead cells and decreases in LC3, ATG5 and BECN1 expression in human normal liver cells, leading to Autophagosome formation inhibition[1].
Glycochenodeoxycholic acid sodium salt (5–500 μM, 24 h) exerts no induction or reduction of TGF-β mRNA expression in KMBC cells and LX-2 cells[2].
Glycochenodeoxycholic acid sodium salt (200 μM, 24 h and 48 h) enhances stemness and chemoresistance of hepatocellular carcinoma cells (HCC) by activating the STAT3 signaling pathway, suppressing the expression of apoptotic genes (Bcl10, Caspase 3, Caspase 4, Tp53, BAD) and increasing the expression of anti-apoptotic genes (Bcl2, Bcl-xl and IL10)[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Glycochenodeoxycholic acid sodium salt Related Antibodies

Apoptosis Analysis[4]

Cell Line: Huh7 and LM3 cell lines
Concentration: 200 μM
Incubation Time: 24 h and 48 h
Result: Increased the cell viability and promoted chemoresistance treated with 5-FU (HY-90006) (120 µg/mL) and cisplatinin (10 µg/mL) in Huh7 and LM3 cell lines

Cell Autophagy Assay[1]

Cell Line: L02 cells
Concentration: 100 μM
Incubation Time: 6 h
Result: Significantly reduced GFP-LC3 puncta and decreased microtubule-associated protein 1 light chain 3 (LC3), autophagy related 5 (ATG5) and beclin 1 (BECN1) expression in L02 cells.

Western Blot Analysis[1]

Cell Line: Human normal liver cells
Concentration: 0-100 μM
Incubation Time: 6 h
Result: Decreased the TFE3 levels in a dose-dependent manner in human normal liver cells.

RT-PCR[2]

Cell Line: KMBC cells
Concentration: 5–500 μM
Incubation Time: 24 h
Result: Unaltered TGF-β mRNA expression in KMBC cells and LX-2 cells.

Real Time qPCR[4]

Cell Line: Huh7 and LM3 cell lines
Concentration: 200 μM
Incubation Time: 24 h and 48 h
Result: Suppressed the expression of apoptotic genes (Bcl10, Caspase 3, Caspase 4, Tp53, BAD) and increased the expression of anti-apoptotic genes (Bcl2, Bcl-xl and IL10) in Huh7 and LM3 cell lines.
Peso molecular

471.61

Fòrmula

C26H42NNaO5
No. CAS
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12[C@](CC[C@]2(00)[C@H](C)CCC(NCC(O[Na])=O)=O)(00)[C@@]3(00)[C@]([C@@]4([C@](C[C@H](O)CC4)(00)C[C@H]3O)C)(00)CC1
Structure Classification
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvente y solubilidad
In Vitro: 

DMSO : 250 mg/mL (530.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 100 mg/mL (212.04 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1204 mL 10.6020 mL 21.2040 mL
5 mM 0.4241 mL 2.1204 mL 4.2408 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 50 mg/mL (106.02 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureza y Documentación
Referencias

Usted podría estar interesado también en los siguientes productos:



Referencia
Descripción
Cond.
Precio Sin IVA
TFEH-PPARg-5
Human PPAR-gamma Activity Assay Kit
 5PlateKit 
TFEH-PPARg-1
Human PPAR-gamma Activity Assay Kit
 1PlateKit 
100-111-50UG
RH TNF-A
 50UG